title: Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
authors.forename: Constantin A
authors.initials: CA
authors.lastname: Dasanu
authors.forename: Robert A
authors.initials: RA
authors.lastname: Schwartz
authors.forename: Frank
authors.initials: F
authors.lastname: Bauer
authors.forename: Lynn K
authors.initials: LK
authors.lastname: Davis
authors.forename: Joel S
authors.initials: JS
authors.lastname: Silver
authors.forename: Michael A
authors.initials: MA
authors.lastname: Reale
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm / Q000235:genetics / Q000502:physiology; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D009196:Myeloproliferative Disorders / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D010677:Philadelphia Chromosome; D011087:Polycythemia Vera / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D013163:Splenomegaly / Q000150:complications / Q000473:pathology; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide